These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 665905)

  • 1. Bedside monitoring of heparin therapy.
    Mollitt DL; Gartner DJ; Madura JA
    Am J Surg; 1978 Jun; 135(6):801-3. PubMed ID: 665905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-blood clotting time, activated partial thromboplastin time, and whole-blood recalcification time as heparin monitoring tests.
    Ts'ao CH; Galluzzo TS; Lo R; Peterson KG
    Am J Clin Pathol; 1979 Jan; 71(1):17-21. PubMed ID: 420167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simplified method for monitoring heparin therapy at the bedside: the activated whole blood clotting time.
    Forman WB; Bayer G
    Am J Hematol; 1981 Nov; 11(3):277-81. PubMed ID: 7315841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between activated clotting time and activated partial thromboplastin times.
    Smythe MA; Koerber JM; Nowak SN; Mattson JC; Begle RL; Westley SJ; Balasubramaniam M
    Ann Pharmacother; 2002 Jan; 36(1):7-11. PubMed ID: 11816262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS; Morris MW; Davey FR
    Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the value of the activated partial thrombo-plastin time (aptt) in monitoring heparin therapy.
    Teien AN; Abildgaard U
    Thromb Haemost; 1976 Jun; 35(3):592-7. PubMed ID: 989966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions.
    Poller L; Thomson JM; Taberner DA
    Ric Clin Lab; 1989; 19(4):363-70. PubMed ID: 2633304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.
    Simko RJ; Tsung FF; Stanek EJ
    Ann Pharmacother; 1995 Oct; 29(10):1015-21; quiz 1061. PubMed ID: 8845539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activated partial thromboplastin time as a monitor of heparin therapy: a warning.
    Makary AZ; Waterbury L
    Johns Hopkins Med J; 1977 Jun; 140(6):311-5. PubMed ID: 864903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients.
    Atallah S; Liebl M; Fitousis K; Bostan F; Masud F
    Perfusion; 2014 Sep; 29(5):456-61. PubMed ID: 24570077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic accuracy of bedside and laboratory coagulation: procedures used to monitor the anticoagulation status of patients treated with heparin.
    Solomon HM; Mullins RE; Lyden P; Thompson P; Hudoff S
    Am J Clin Pathol; 1998 Apr; 109(4):371-8. PubMed ID: 9535388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose heparin in routine hemodialysis monitored by activated partial thromboplastin time.
    Shapiro WB; Faubert PF; Porush JG; Chou SY
    Artif Organs; 1979 Feb; 3(1):73-7. PubMed ID: 435127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
    Lang M; Fey MF; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization.
    Scialla SJ
    Am J Clin Pathol; 1985 Sep; 84(3):351-4. PubMed ID: 4036867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control and complications of intermittent heparin therapy.
    Norman CS; Provan JL
    Surg Gynecol Obstet; 1977 Sep; 145(3):338-42. PubMed ID: 888052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support.
    Moynihan K; Johnson K; Straney L; Stocker C; Anderson B; Venugopal P; Roy J
    Perfusion; 2017 Nov; 32(8):675-685. PubMed ID: 28693359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.
    Heyns AD; van den Berg DJ; Kleynhans PH; du Toit PW
    J Clin Pathol; 1981 Jan; 34(1):63-8. PubMed ID: 7462439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.
    Kubalek R; Berlis A; Schwab M; Klisch J; Schumacher M
    Neuroradiology; 2003 May; 45(5):325-7. PubMed ID: 12669158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.